Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923232 · ClinicalTrials.gov registry record · NA
Ocular Adaptation and Visual Performance for Accommodative Contact Lens
A NA study, sponsored by Pacific University.
- Terminated
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT02923232: Clinical Trial NA study, sponsored by Pacific University.
NCT02923232 is a NA study that was terminated before completion, run by Pacific University. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02923232, a NA study, was terminated before completion, sponsored by Pacific University.
- TERMINATED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
Presbyopes (people who might have a significant loss of their ability to accommodate their crystalline lens in the eye) will be recruited to wear a test lens and perform typical clinical tests of visual acuity with different luminance levels and viewing distances/angles.
Primary Outcome
Participants will wear the test lens and look at different downsize angles. The refractive power of the lens/eye combination will be measured with an open-field auto refractor.
Interventions
- DEVICE Accommodative contact lens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-11 |
| Est. Completion | 2020-03-01 |
| Phase | NA |
Why NCT02923232 stopped before completion
NCT02923232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Accommodative contact lens is the first listed.
NCT02923232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02923232 about?
NCT02923232 is a clinical study titled "Ocular Adaptation and Visual Performance for Accommodative Contact Lens". Presbyopes (people who might have a significant loss of their ability to accommodate their crystalline lens in the eye) will be recruited to wear a test lens and perform typical clinical tests of visual acuity with different luminance levels and viewing distances/angles.
What is the current status of trial NCT02923232?
This trial is currently terminated. It is a NA study. The enrollment target is 52 participants. The study started on 2014-11. Estimated completion is 2020-03-01.
What interventions are being tested in trial NCT02923232?
The interventions under investigation include: Accommodative contact lens (DEVICE).
Who is sponsoring clinical trial NCT02923232?
This trial is sponsored by Pacific University, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02923232's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia